Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, observer-blind, active-controlled phase III study to demonstrate the superior efficacy of GSK Biologicals' adjuvanted influenza candidate vaccine [GSK2186877A], administered intramuscularly in elderly aged 65 years or above, as compared to Fluarix

Next Previous
Trial Profile

A randomized, observer-blind, active-controlled phase III study to demonstrate the superior efficacy of GSK Biologicals' adjuvanted influenza candidate vaccine [GSK2186877A], administered intramuscularly in elderly aged 65 years or above, as compared to Fluarix

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary) ; AS03A
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms INFLUENCE 65
  • Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK

Most Recent Events

  • 18 Jun 2012 Actual patient number changed from 43812 to 43695 as reported by ClinicalTrials.gov.
  • 28 Mar 2011 Actual end date changed from May 2010 to Dec 2010 as reported by ClinicalTrials.gov.
  • 28 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top